It is becoming increasingly evident that the etiology of lung cancer involves a combination of both environmental and hereditary factors and that individuals may vary substantially in their genetic susceptibility to carcinogens such as tobacco. The primary goal of this project is to identify individuals genetically predisposed to be at very high risk. To do so we will establish a population-based lung cancer registry consisting of approximately 2 million. We will collect demographic, family history, and smoking data on lung cancer patients and family members. Blood samples will be collected and stored in conjunction with the SPORE Pathology Resource Core (Core B). We will perform segregation analysis on these families to fit genetic and environmental hypotheses and determine the best model characterizing familial aggregation of lung cancer (Aim 1). In doing so, we will also identify specific kindreds which will be useful for subsequent genetic linkage and candidate gene studies. Proband clinical characteristics which may be associated with increased cancer risk to family members will be determined. Sensitivity of peripheral blood lymphocyte DNA to mutagen-induced chromatid breaks will be assessed in lung cancer patients with an without a family history of lung cancer (Aim 2). In addition, we will compare patterns of allele loss in lung cancers from lung cancer patients with a family history of lung cancer and will determine if different patterns of allele loss occur in familial tumors (Aim 3). This part of the project will be closely integrated with Project #3, Molecular Markers for Early Lung Cancer Detection and Project 1, Identification of 3p Recessive Oncogenes in Lung Cancer. Moreover, this project could interact closely with Developmental Project 1 in determining patterns of potential inherited predisposition to nicotine dependency within lung cancer prone families. In addition to addressing the Specific Aims, one of the most important translational applications of this proposal will be the identification of a cohort of asymptomatic individuals who, because of a genetic predisposition, may be candidates for future development of lung cancer chemoprevention trials, a goal of Project #4, or the development of early detection strategies, a goal of Project #3.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-03S2
Application #
6103221
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
City
Dallas
State
TX
Country
United States
Zip Code
75390
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Huang, Fang; Ni, Min; Chalishazar, Milind D et al. (2018) Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metab 28:369-382.e5
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Pozo, Karine; Minna, John D; Johnson, Jane E (2018) Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. Genes Dev 32:865-867
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Cascone, Tina; McKenzie, Jodi A; Mbofung, Rina M et al. (2018) Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27:977-987.e4
Fan, C-W; Yarravarapu, N; Shi, H et al. (2018) A synthetic combinatorial approach to disabling deviant Hedgehog signaling. Sci Rep 8:1133
Ng, Patrick Kwok-Shing; Li, Jun; Jeong, Kang Jin et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33:450-462.e10
Cascone, Tina; Gold, Kathryn A; Swisher, Stephen G et al. (2018) Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105:418-424

Showing the most recent 10 out of 1059 publications